Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide. (Q47868741)

From Wikidata

Jump to navigation Jump to search

scientific article published in June 2017

Language	Label	Description	Also known as
English	Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide.	scientific article published in June 2017

Statements

scholarly article

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/28573765

Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide. (English)

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/28573765

Hertzel C. Gerstein

1

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/28573765

Lawrence A Leiter

24

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/28573765

Ernesto German Cardona MuÑoz

26

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/28573765

Markolf Hanefeld

19

object named as

Markolf Hanefeld

1 reference

Europe PubMed Central

6 February 2018

Theodora Temelkova-Kurktschiev

32

object named as

Theodora Temelkova-Kurktschiev

1 reference

Europe PubMed Central

6 February 2018

object named as

Nicolae Hancu

18

0 references

17

object named as

Edward Franek

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/28573765

12

object named as

Alvaro Avezum

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/28573765

author name string

Helen M Colhoun

2

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/28573765

Gilles R Dagenais

3

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/28573765

Rafael Diaz

4

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/28573765

Mark Lakshmanan

5

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/28573765

Prem Pais

6

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/28573765

Jeffrey Probstfield

7

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/28573765

Matthew C Riddle

8

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/28573765

Lars Rydén

9

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/28573765

Denis Xavier

10

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/28573765

Charles M Atisso

11

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/28573765

Jan Basile

13

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/28573765

Namsik Chung

14

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/28573765

Ignacio Conget

15

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/28573765

William C Cushman

16

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/28573765

Shaun Holt

20

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/28573765

Petr Jansky

21

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/28573765

Matyas Keltai

22

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/28573765

Fernando Lanas

23

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/28573765

Patricio Lopez-Jaramillo

25

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/28573765

Valdis Pirags

27

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/28573765

Nana Pogosova

28

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/28573765

Peter J Raubenheimer

29

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/28573765

Jonathan Shaw

30

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/28573765

Wayne H-H Sheu

31

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/28573765

REWIND Trial Investigators

33

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/28573765

publication date

1 June 2017

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/28573765

Diabetes, Obesity and Metabolism

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/28573765

20

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/28573765

42-49

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/28573765

1

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/28573765

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13028

21 January 2018

Dysglycaemia, vasculopenia, and the chronic consequences of diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13028

21 January 2018

9. Cardiovascular Disease and Risk Management

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13028

21 January 2018

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13028

21 January 2018

Telmisartan, ramipril, or both in patients at high risk for vascular events

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13028

21 January 2018

Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13028

21 January 2018

Long-term follow-up after tight control of blood pressure in type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13028

21 January 2018

RETRACTED: Primary Prevention of Cardiovascular Disease with a Mediterranean Diet

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13028

21 January 2018

Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13028

21 January 2018

Intensive glucose control and macrovascular outcomes in type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13028

21 January 2018

Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13028

21 January 2018

10-year follow-up of intensive glucose control in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13028

21 January 2018

Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13028

21 January 2018

Nine-Year Effects of 3.7 Years of Intensive Glycemic Control on Cardiovascular Outcomes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13028

21 January 2018

A randomized trial of therapies for type 2 diabetes and coronary artery disease

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13028

21 January 2018

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13028

21 January 2018

Basal insulin and cardiovascular and other outcomes in dysglycemia

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13028

21 January 2018

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13028

21 January 2018

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13028

21 January 2018

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13028

21 January 2018

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13028

21 January 2018

Cardiovascular biology of the incretin system

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13028

21 January 2018

GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13028

21 January 2018

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13028

21 January 2018

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13028

21 January 2018

Dulaglutide: first global approval

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13028

21 January 2018

Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13028

21 January 2018

Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13028

21 January 2018

ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Summary

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13028

21 January 2018

Vascular protection in people with diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13028

21 January 2018

Graphical approaches for multiple comparison procedures using weighted Bonferroni, Simes, or parametric tests

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13028

21 January 2018

A graphical approach to sequentially rejective multiple test procedures

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13028

21 January 2018

Advanced multiplicity adjustment methods in clinical trials

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13028

21 January 2018

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.13028

21 January 2018

Identifiers

10.1111/DOM.13028

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/28573765

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/28573765

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47868741&oldid=1701031294"